Back to Search Start Over

Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment

Authors :
Ramos, Daniel M.
d'Ydewalle, Constantin
Gabbeta, Vijayalakshmi
Dakka, Amal
Klein, Stephanie K.
Norris, Daniel A.
Matson, John
Taylor, Shannon J.
Zaworski, Phillip G.
Prior, Thomas W.
Snyder, Pamela J.
Valdivia, David
Hatem, Christine L.
Waters, Ian
Gupte, Nikhil
Swoboda, Kathryn J.
Rigo, Frank
Bennett, C. Frank
Naryshkin, Nikolai
Paushkin, Sergey
Crawford, Thomas O.
Sumner, Charlotte J.
Source :
Journal of Clinical Investigation. November, 2019, Vol. 129 Issue 11, p4817, 15 p.
Publication Year :
2019

Abstract

BACKGROUND. Spinal muscular atrophy (SMA) is caused by deficient expression of survival motor neuron (SMN) protein. New SMN-enhancing therapeutics are associated with variable clinical benefits. Limited knowledge of baseline and drug-induced SMN levels in disease-relevant tissues hinders efforts to optimize these treatments. METHODS. SMN mRNA and protein levels were quantified in human tissues isolated during expedited autopsies. RESULTS. SMN protein expression varied broadly among prenatal control spinal cord samples, but was restricted at relatively low levels in controls and SMA patients after 3 months of life. A 2.3-fold perinatal decrease in median SMN protein levels was not paralleled by comparable changes in SMN mRNA. In tissues isolated from nusinersen-treated SMA patients, antisense oligonucleotide (ASO) concentration and full-length (exon 7 including) SMN2 (SMN2-FL) mRNA level increases were highest in lumbar and thoracic spinal cord. An increased number of cells showed SMN immunolabeling in spinal cord of treated patients, but was not associated with an increase in whole-tissue SMN protein levels. CONCLUSIONS. A normally occurring perinatal decrease in whole-tissue SMN protein levels supports efforts to initiate SMN-inducing therapies as soon after birth as possible. Limited ASO distribution to rostral spinal and brain regions in some patients likely limits clinical response of motor units in these regions for those patients. These results have important implications for optimizing treatment of SMA patients and warrant further investigations to enhance bioavailability of intrathecally administered ASOs. FUNDING. SMA Foundation, SMART, NIH (R01-NS096770, R01-NS062869), Ionis Pharmaceuticals, and PTC Therapeutics. Biogen provided support for absolute real-time RT-PCR.<br />Introduction The neuromuscular disease spinal muscular atrophy (SMA), affecting approximately 1 in 10,000 individuals, is the most common inherited cause of infant death (1). The most frequent and severe type [...]

Details

Language :
English
ISSN :
00219738
Volume :
129
Issue :
11
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.609854891
Full Text :
https://doi.org/10.1172/JCI124120